Sign up to access historical data
Similar companies
| Company | Est. Transaction Value | |
|---|---|---|
 |
Gilead SciencesGILD |
-$8,000 |
 |
AmgenAMGN |
$67,000 |
 |
Editas MedicineEDIT |
-$8,000 |
 |
Alnylam PharmaceuticalsALNY |
-$16,000 |
 |
RegeneronREGN |
-$57,000 |
Trades by US Politicians
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Michael McCaul Republican | May 12, 2023 | Sell | $15K - $50K |
| Michael McCaul Republican | May 12, 2023 | Sell | $100K - $250K |
Who is the latest politician to buy or sell United Therapeutics shares?
Michael McCaul sold United Therapeutics shares most recently on May 12, 2023.
Which politician has sold the most UTHR stock over the last two years?
Michael McCaul has sold the most UTHR stock in the last 2 years, with an estimated value of $210,000.
What is the total value of politicians trading UTHR stock in the last 2 years?
The net value of trades by US politicians for United Therapeutics in the last 2 years is negative, amounting to -$210,000. This suggests that US politicians do not believe in the success of the company for various reasons.
How do insider transactions over the last 2 years reflect on United Therapeutics' market confidence?
Over the last 2 years, insider transactions for United Therapeutics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering politicians might have insights or reasons not immediately apparent to the public.
Why should individual investors pay attention to the stock transactions of US politicians?
Monitoring US politicians' stock trades is valuable because they may have inside information about upcoming policies that could affect stock values, providing investors with valuable clues for making informed decisions.
